Page 5 - Genscript Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ GenScript USA Inc., the world s leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The kit, which has been authorized by the FDA for emergency use in clinical diagnostics laboratories, is the first commercially available product to specifically detect COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity. ....

Hong Kong , New Jersey , United States , David Martz , Hong Kong Stock Exchange , Genscript Biotech Corporation Stock Code , Health Sciences Authorities , Drug Administration Center , Genscript Biotech Corporation , Life Science Group At Genscript , Prnewswire Genscript United States Inc , Script United States Inc , Drug Administration , Biologics Evaluation , Antibody Detection Kit , Life Science Group , Script Biotech Corporation , Stock Code , Mainland China , Health Care Amp Hospitals , Medical Pharmaceuticals , ஹாங் காங் , புதியது ஜெர்சி , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் மார்ட்ஸ் , ஹாங் காங் ஸ்டாக் பரிமாற்றம் ,